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Expression of Bacillus Anthracis Protective Antigen in Transgenic Chloroplasts of
Tobacco, a Non-Food/Feed Crop
Abstract
The Centers for Disease Control (CDC) lists Bacillus anthracis as a category A agent and estimates the
cost of an anthrax attack to exceed US$ 26 billion per 100,000 exposed individuals. Concerns regarding
anthrax vaccine purity, a requirement for multiple injections, and a limited supply of the protective antigen
(PA), underscore the urgent need for an improved vaccine. Therefore, the 83 kDa immunogenic Bacillus
anthracis protective antigen was expressed in transgenic tobacco chloroplasts. The PA gene (pag) was
cloned into a chloroplast vector along with the psbA regulatory signals to enhance translation.
Chloroplast integration of the transgenes was confirmed by PCR and Southern blot analyses. Crude plant
extracts contained up to 2.5 mg full length PA/g of fresh leaf tissue and this showed exceptional stability
for several months in stored leaves or crude extracts. Maximum levels of expression were observed in
mature leaves under continuous illumination. Co-expression of the ORF2 chaperonin from Bacillus
thuringiensis did not increase PA accumulation or induce folding into cuboidal crystals in transgenic
chloroplasts. Trypsin, chymotrypsin and furin proteolytic cleavage sites present in PA were protected in
transgenic chloroplasts because only full length PA 83 was observed without any degradation products.
Both CHAPS and SDS detergents extracted PA with equal efficiency and PA was observed in the soluble
fraction. Chloroplast-derived PA was functionally active in lysing mouse macrophages when combined
with lethal factor (LF). Crude leaf extracts contained up to 25 μg functional PA/ml. With an average yield
of 172 mg of PA per plant using an experimental transgenic cultivar grown in a greenhouse, 400 million
doses of vaccine (free of contaminants) could be produced per acre, a yield that could be further
enhanced 18-fold using a commercial cultivar in the field.
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Expression of Bacillus anthracis protective antigen in transgenic
chloroplasts of tobacco, a non-food/feed crop
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The Centers for Disease Control (CDC) lists Bacillus anthracis as a category A agent and
estimates the cost of an anthrax attack to exceed US$ 26 billion per 100,000 exposed individuals.
Concerns regarding anthrax vaccine purity, a requirement for multiple injections, and a limited
supply of the protective antigen (PA), underscore the urgent need for an improved vaccine.
Therefore, the 83 kDa immunogenic Bacillus anthracis protective antigen was expressed in
transgenic tobacco chloroplasts. The PA gene (pag) was cloned into a chloroplast vector along
with the psbA regulatory signals to enhance translation. Chloroplast integration of the transgenes
was confirmed by PCR and Southern blot analyses. Crude plant extracts contained up to 2.5 mg
full length PA/g of fresh leaf tissue and this showed exceptional stability for several months in
stored leaves or crude extracts. Maximum levels of expression were observed in mature leaves
under continuous illumination. Co-expression of the ORF2 chaperonin from Bacillus thuringiensis
did not increase PA accumulation or induce folding into cuboidal crystals in transgenic
chloroplasts. Trypsin, chymotrypsin and furin proteolytic cleavage sites present in PA were
protected in transgenic chloroplasts because only full length PA 83 was observed without any
degradation products. Both CHAPS and SDS detergents extracted PA with equal efficiency and
PA was observed in the soluble fraction. Chloroplast-derived PA was functionally active in lysing
mouse macrophages when combined with lethal factor (LF). Crude leaf extracts contained up to
25 μg functional PA/ml. With an average yield of 172 mg of PA per plant using an experimental
transgenic cultivar grown in a greenhouse, 400 million doses of vaccine (free of contaminants)
could be produced per acre, a yield that could be further enhanced 18-fold using a commercial
cultivar in the field.
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1. Introduction
Recent occurrences of the inadvertent contamination of the food supply by plant-derived
pharmaceutical proteins have resulted in heavy penalties, stricter USDA guidelines and a US
government proposal to seize food products tainted with traces of pharmaceutical crops.
These incidents underscore the need to produce pharmaceutical proteins in non-food or feed
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crops. At the same time, the inability of large parts of the human population to afford newly
developed human vaccines and therapeutics requires that agricultural scale production be
developed for their manufacture. However, this must be achieved in an environmentally
friendly manner, without contaminating our food crops. This article describes use of an
alternate non-food and non-feed crop to produce recombinant protective antigen (PA)
(vaccine antigen) against an agent of bioterrrorism, via chloroplast genetic engineering.
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Chloroplasts are ideal for genetic engineering because they offer a number of attractive
advantages, including high-level transgene expression [1], multi-gene engineering in a
single transformation event [2–4], transgene containment via maternal inheritance [5], lack
of gene silencing [2,6], position effect due to site-specific transgene integration [1] and
pleiotropic effects [6,7]. Random integration of transgenes via non-homologous
recombination results in nuclear transgenic lines with extremely high variability of foreign
gene expression and this requires screening of hundreds of independent transformation
events. Such a screening is not necessary in chloroplast transgenic lines because of uniform
foreign gene expression in chloroplast transgenic lines due to site specific integration of
transgenes via homologous recombination of flanking sequences present in chloroplast
transformation vectors. Similarly, pleiotrophic effects are often observed when foreign
genes are expressed via the nuclear genome. For example, cholera toxin β subunit was
expressed in leaves of nuclear transgenic plants, they were unable to grow even with very
low levels of CTB expression [8]. However, when CTB was expressed to 410–3300-fold
higher levels in transgenic chloroplasts, plants grew normally like the untransformed control
[7,9].
Chloroplast genetic engineering is most suitable for hyper-expression of vaccine antigens
and production of valuable therapeutic proteins. Since demonstrating expression of human
elastin-derived polymers for various biomedical applications [10], we have extended this
approach to express vaccines antigens for cholera [7], monoclonal antibody [11] and human
therapeutic proteins, including human serum albumin [12], magainin, a broad spectrum
topical agent, systemic antibiotic, wound healing stimulant and a potential anticancer agent
[13], interferon [14] and insulin-like growth factor [14]. Several other laboratories have
expressed other therapeutic proteins, including human somatotropin [15] and interferonGUS fusion proteins [16] in transgenic chloroplasts.
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Tobacco, a non-food and non-feed crop, is easy to manipulate through genetic engineering,
and can produce large amounts of biomass. Both nuclear and chloroplast genomes of
tobacco have been transformed with ease. Tobacco is a self-pollinating crop and there are no
known wild or cultivated relatives in North America. Several studies have demonstrated that
transgenes are maternally inherited when introduced into the chloroplast genome of tobacco
[1]. Most importantly, harvesting tobacco leaves before the onset of flowering eliminates
transgene flow via pollen or seed, thereby preventing contamination of food crops as is
required by various regulatory agencies. Tobacco is an excellent biomass producer (in
excess of 40 t fresh leaf weight/acre based on multiple mowings per season) and a prolific
seed producer (up to one million seeds produced per plant), thus shortening the time in
which a product can be scaled up and brought to market. The existence of a large-scale
processing infrastructure is yet another advantage for tobacco. Tobacco is also an ideal
choice because of the need to explore alternate uses for this crop. Although many tobacco
cultivars produce high levels of alkaloids, there are low-alkaloid varieties that can be used
for the production of pharmaceutical proteins. Fortunately, alkaloids are easily separated
from proteins during purification and any cross contamination can be virtually eliminated.
Cramer et al. [17] provide data to support some of the advantages listed above.
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Anthrax is a zoonosis, a disease shared by animals and humans. Ruminants such as cattle,
sheep, goats, and deer are the most susceptible and commonly affected animals. Animals
contract the disease through ingestion of soil-borne Bacillus anthracis spores and may die
acutely. Anthrax is endemic to the United States. Most recent outbreaks of anthrax in deer
and livestock occurred in September 2001 in the Del Rio, TX, region (USDA, 2002, fact
sheet) and in South Dakota. The handling of infected animals or animal products sometimes
leads to human infections. The threat of anthrax has increased due to recent bioterrrorism
activities.
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Bacillus anthracis is a Gram-positive, nonmotile, aerobic or facultatively anaerobic, sporeforming bacterium. The spores are about 1 μm in size, extremely hardy, resistant to gamma
rays, UV light, drying, heat, and many disinfectants [18,19]. Anthrax infects humans
through contact with the spores in one of three ways. First, cutaneous anthrax occurs when
spores enter the body through a cut or an abrasion on the skin or through the bite of an insect
that has recently fed on an infected animal. Second, gastrointestinal anthrax occurs through
consumption of contaminated meat products. Third, inhalational anthrax ensues when an
animal encounters aerosolized spores that are able to reach lung alveoli [18]. In humans,
cutaneous anthrax is the most common form with approximately 2000 cases reported each
year worldwide. Gastrointestinal cases are rare and usually occur in small outbreaks.
Historically, inhalation anthrax most often occurred in factories that handled animal hides
and wool. Nowadays, the threat of biological warfare or terrorism is the principal reason for
concern about inhalation anthrax. Prior to 2001, there had been no reports of inhalation
anthrax in the US since 1978 [19].
When spores enter the body, macrophages engulf them, migrate to regional lymph nodes and
the spores germinate into vegetative bacteria. Spores germinate upon entering an
environment rich in glucose, amino acids, and nucleosides, such as in animal and human
tissues and blood. Macrophages release the vegetative bacteria and they spread through the
blood and lymph until there are up to 108 bacilli per milliliter of blood. The exotoxins are
produced from bacteria that lead to symptoms and possible death [18]. The vegetative cells
enter the spore state when the nutrients are exhausted or when the organisms are exposed to
molecular oxygen in the air [19]. Spores can survive in the lungs or lymph nodes up to 60
days before germination occurs. In animal experiments, it has been seen that once toxin
secretion has reached a critical threshold, death will occur, even if the blood is rendered free
of Bacillus anthracis through the use of antibiotics. From primate studies, the estimated
lethal dose of inhaled anthrax spores sufficient to kill 50% of humans exposed to it (the
LD50) is 2500–55,000 spores per treated individual [19].

NIH-PA Author Manuscript

The Centers for Disease Control (CDC) lists anthrax as a category A disease agent and
estimates the cost of an anthrax attack would be US$ 26.2 billion per 100,000 persons
exposed [20]. The only vaccine licensed for human use in the US, Biothrax (formerly
Anthrax vaccine adsorbed, or AVA), is an aluminum hydroxide-adsorbed, formalin-treated
culture supernatant of a toxigenic, nonencapsulated, non-proteolytic strain of Bacillus
anthracis [21]. In addition to the immunogenic protective antigen, the vaccine contains trace
amounts of edema factor (EF) and lethal factor (LF) that may contribute to the high rate of
local reactions at the site of the subcutaneous injection or reported to be toxic causing sideeffects [22–24]. However LF alone may enhance vaccine immunogenicity [22]. There is a
clear need and urgency for an improved vaccine for anthrax and for improved production
methods that allow it to be mass-produced at reasonable cost.
Using chloroplast transformation technology, large quantities of PA could be produced in
transgenic plants due to the presence of thousands of copies of transgenes per cell as
opposed to only a few copies in nuclear transgenic plants. Transgenic chloroplast technology
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has been used to hyper-express bacterial proteins—up to 46% of total soluble protein (TSP)
from Bacillus genes, the highest ever reported in transgenic plants [2]. Chloroplasts are
prokaryotic in nature and express native bacterial genes (like β subunit of cholera toxin) at
very high levels (410-fold [7] or 3300-fold [9] higher than nuclear expression). This is in
sharp contrast to nuclear expression of pag, that would require extensive codon
modifications because of high AT content, unfavorable codons, presence of mRNA
destabilizing sequences, and cryptic polyadenylation or splice sites. Chloroplast
transformation typically utilizes two flanking sequences that, through homologous
recombination, insert transgenes into spacer regions between functional genes of the
chloroplast genome, thus targeting transgenes to a known location [1]. The chloroplast
genome may be engineered without the use of antibiotic resistance genes as well for the
development of edible vaccines [25]. Therefore, pag was expressed in transgenic tobacco
chloroplasts in order to obtain large amounts of PA free of contaminants and to facilitate
vaccine production to stockpile for times of crisis.

2. Materials and methods
2.1. Construction of chloroplast vectors

NIH-PA Author Manuscript

The pMS1 plasmid containing pag gene provided by Rakesh Bhatnagar (Centre for
Biotechnology, Jawaharlal Nehru University, India) was digested with unique restriction
sites BglII and BamHI and cloned into the plasmid p-BlueScript. The psbA 5′-UTR was
amplified, introducing two unique restriction sites EcoRV and SalI at 5′-end and NdeI site
on the 3′-end. The PCR product was sequenced and cloned into the pCR 2.1 vector. The pBlue-T7-pag plasmid was digested with NdeI and XbaI to remove the pag gene and it was
sub-cloned into pCR 2.1–5′-UTR. The pCR 2.1–5′-UTR-pag vector was digested with
EcoRV and XbaI and the 5′-UTR-pag is cloned into chloroplast vector pLD. The final
construct was designated pLD-JW1. The pLD-JW1 vector was digested with EcoRV and
ligated with the ORF1, 2 promoter and putative chaperonin flanked by EcoRV restriction
sites and the resultant construct was designated pLD-JW2.
2.2. Bombardment and selection of transgenic plants
Sterile Nicotiana tabacum cv. Petit Havana tobacco leaves were bombarded using the BioRad PDS-1000/He biolistic device as previously described [26,27]. The bombarded leaves
were placed on RMOP medium containing 500 μg/ml spectinomycin for two rounds of
selection on plates and subsequently moved to jars of MSO medium containing 500 μg/ml
spectinomycin.
2.3. PCR analysis to test stable integration
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DNA was extracted from tobacco leaves using Qiagen DNeasy Plant Mini Kit (Qiagen,
Valencia, CA). PCR was performed using the Perkin-Elmer Gene Amp PCR System 2400
(Perkin-Elmer, Chicago, IL). PCR reactions contained template DNA, 1× Taq buffer, 0.5
mM dNTPs, 0.2 mM 3P primer, 0.2 mM 3 M primer, 0.05 units/μl Taq polymerase, and 0.5
mM MgCl2. Samples were run for 30 cycles as follows: 95 °C for 1 min, 65 °C for 1 min,
and 72 °C for 2 min with a 5 min ramp up at 95 °C and a 72 °C hold for 10 min after all 30
cycles were completed. PCR products were separated on 1% agarose gels.
2.4. Southern blot analysis
Total plant DNA was digested with BglII and run on a 0.8% agarose gel at 50 V for 2 h. The
gel was soaked in 0.25 N HCl for 15 min and then rinsed 2× with water. The gel was soaked
in transfer buffer (0.4 N NaOH, 1 M NaCl) for 20 min and then transferred overnight to a
nitrocellulose membrane. The membrane was rinsed twice in 2× SSC (0.3 M NaCl, 0.03 M
sodium citrate), dried on filter paper, and then crosslinked in the GS GeneLinker
Vaccine. Author manuscript; available in PMC 2012 October 26.
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(Stratagene, La Jolla, CA). The flanking sequence probe was made by digesting pUC-CT
vector DNA with BamHI and BglII to generate a 0.81 kb probe [6]. The pag probe was
made by digesting pag with NcoI to generate a 0.52 kb probe. The probes were labeled
with 32P using the ProbeQuant G-50 Micro Columns (Amersham, Arlington Heights, IL).
The probes were hybridized with the membranes using Stratagene QUICK-HYB
hybridization solution and protocol (Stratagene, La Jolla, CA).
2.5. Western blot analysis
Approximately 100 mg of leaf tissue was ground in liquid nitrogen with a mortar and pestle
and stored at −80 °C for several months. When it was time to extract the proteins, the
powder was removed from −80 °C and mixed with a mechanical pestle in 200 μl of plant
extraction buffer (0.1% SDS, 100 mM NaCl, 200 mM Tris–HCl pH 8.0, 0.05% Tween 20,
400 mM sucrose, 2 mM PMSF). The plant extract was then centrifuged for 5 min at 10,000
× g to pellet the insoluble plant material. The supernatant containing the extracted protein
was transferred to a fresh tube and an aliquot was taken out, combined with sample loading
buffer, boiled, and then run on 8% SDS–PAGE gels for 1 h at 80 V, then 2 h at 150 V. Gels
were transferred overnight at 10 V to nitrocellulose membrane. The membrane was blocked
with PTM (1 × PBS, 0.05% Tween 20, and 3% dry milk). PA was detected with anti-PA
monoclonal antibody 14B7. Secondary antibody used was goat anti-mouse IgG conjugated
to horseradish peroxidase (American Qualex Antibodies, A106PN).
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The stability assay utilized SDS buffer (0.1% SDS, 100 mM NaCl, 10 mM EDTA, 200 mM
Tris–HCl pH 8.0, 0.05% Tween 20, 14 mM β-mercaptoethanol, 400 mM sucrose, 2 mM
PMSF) and CHAPS buffer (4% CHAPS, 100 mM NaCl, 10 mM EDTA, 200 mM Tris–HCl
pH 8.0, 14 mM β-mercaptoethanol, 400 mM sucrose, 2 mM PMSF). Two hundred μl of
each buffer was added to 100 mg powdered leaf tissue. For supernatant fractions, the
extraction was centrifuged at 10,000× g for 5 min and supernatant was removed. For
homogenate, the entire extract was used. The samples were stored at 4 °C and −20 °C for 2
days. The rest of the western protocol was the same as described above.
2.6. Estimation of total soluble protein
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The total soluble protein of the leaf samples was estimated using the Bio-Rad Bradford
Protein Assay. Leaf samples of transformed and untransformed plants (100 mg) were ground
in liquid nitrogen. Plant protein extraction buffer (15 mM Na2CO3, 35 mM NaHCO3, 3 mM
NaN3, pH 9.6, 0.1% Tween, 5 mM PMSF) was used to resuspend the ground mixture. The
mechanical pestle was used to finely grind the leaf powder and resuspend the proteins in the
buffer. The bovine serum albumin (BSA) standard curve was obtained by diluting BSA in
plant extraction buffer. Each standard and sample (10 μl) was added in duplicate to
microtiter plate wells. Diluted Biorad dye reagent (200 μl) was added to each well. The
sample and the dye were thoroughly mixed. The plate was incubated at room temperature
for 5–10 min and read on a plate reader at 630 nm.
2.7. ELISA
The PA quantification was done using the enzyme linked immunosorbent assay (ELISA).
The standards, test samples and antibody were diluted in coating buffer (15 mM Na2CO3, 35
mM NaHCO3, 3 mM NaN3, pH 9.6). The standards ranging from 50 to 1000 ng were made
by diluting purified PA in coating buffer. The leaf samples were collected from plants
exposed to regular lighting pattern (16 h light and 8 h dark), 3 day continuous light, and 5
day continuous light. The standards and protein samples (100 μl) were coated to 96-well
polyvinyl chloride microtiter plate (Cell-star) for 1 h at 37 °C followed by washing with
PBST and water. The background was blocked with fat-free milk in PBS and Tween and
incubated for 1 h followed by washing. The primary anti-PA antibody (Immuno Chemicals)
Vaccine. Author manuscript; available in PMC 2012 October 26.
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diluted (1:1000) in PBST containing milk powder was loaded into wells and incubated for 1
h. The wells were then washed and incubated with 100 μl of anti-mouse IgG-HRP
conjugated antibody made in goat (American Qualex) (1: 5000) diluted in PBST containing
milk powder. The plate was then incubated for 1 h at 37 °C. After the incubation the plate
was washed thrice with PBST and with water. The wells were then loaded with 100 μl of
3,3′,5,5′-tetramethyl benzidine (TMB from American Qualex) substrate and incubated for
10–15 min at room temperature. The reaction was terminated by addition of 50 μl of 2N
sulfuric acid per well and the plate was read on a plate reader (Dynex Technologies) at 450
nm.
2.8. Macrophage lysis assays
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Approximately 100 mg of powdered leaf tissue was extracted with 200 μl of extraction
buffer. For the supernatant fraction, the buffer and tissue were centrifuged for 5 min at
10,000 × g and the supernatant was placed in a new tube. For the homogenate, all of the
tissue and the buffer was assayed. RAW264.7 macrophage cells were plated in 96-well
plates in 120 μl DMEM medium and grown to 50% confluence. The medium was aspirated
and replaced with 100 μl medium containing 250 ng/ml LF. The control plate received
medium with no LF to test toxicity of plant material and buffers. In separate 96-well plates,
the plant samples were diluted serially two-fold and 40 μl of the dilutions were transferred
onto the RAW264.7 cells so the top row had plant extract at 1:14 dilution. MTT (3-[4,5dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) was added after 5–10 h to assess
cell death [28].

3. Results and discussion
3.1. Chloroplast vectors
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The pLD-JW1 vector (8.3 kb, see Fig. 1A) was constructed to transform tobacco
chloroplasts. This construct is based on the vector pLD that was used successfully in
previous publications from this laboratory [2,7]. The trnI and trnA chloroplast genes were
used as flanking sequences for homologous recombination to insert a pag-containing
cassette into the spacer region between the two tRNA genes in the inverted repeat region of
the chloroplast genome, as reported previously [10,29]. The pag gene has an ORF of 2315
bp of which 2205 encode for 735 amino acids. The rest of the region encodes the signal
peptide, which was not included in the cassette. The constitutive 16 s rRNA promoter, which
can be recognized by both the chloroplast encoded RNA polymerase and the nuclear
encoded RNA polymerase, was used to drive transcription of the aadA and pag genes. The
aadA gene conferring spectinomycin resistance was used for selection of transgenic shoots.
The pag gene coding for anthrax protective antigen was regulated by the psbA 5′ and 3′
elements. The 5′-UTR from psbA, including its promoter, was used for transcription
enhancement of the pag gene and for translation enhancement as it has several sequences for
ribosomal binding sites. It acts as a scaffold for the light regulated proteins involved in
ribosomal binding to enhance translation [12] and the 3′-UTR region conferred transcript
stability [1].
Since very high expression of the Cry2A2 protein of Bacillus thuringiensis was observed (up
to 46% total soluble protein [2]), a second construct was made by adding orf1, 2 from B.
thuringiensis to the pLD-JW1 vector, forming the pLD-JW2 vector (see Fig. 1B). The orf1,
2 gene codes for a putative chaperone [30]. Including the orf1, 2 gene was done to test
whether the putative chaperone could fold a heterologous Bacillus protein (i.e., PA) into
cuboidal crystals or form inclusion bodies, protect PA from proteolytic degradation, and
facilitate purification.
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Chloroplast transgenic lines were generated by particle bombardment as described
previously [26,27]. After bombarding Nicotiana tabacum cv. Petit Havana tobacco leaves
with the chloroplast vectors, the leaves were grown on selective medium containing 500 μg/
ml spectinomycin. Three different genetic events can produce spectinomycin-resistant
tobacco shoots: (1) transgene integration into the chloroplast genome; (2) the nuclear
genome; or (3) spontaneous mutants. PCR with two specific primers, 3P and 3M, allowed
identification of shoots having the desired chloroplast transgene integration. The 3P primer
annealed to the native chloroplast genome and the 3M primer annealed to the aadA gene
(see Fig. 1C). Nuclear transformants were eliminated because 3P will not anneal and
mutants were ruled out because 3 M will not anneal. At least 50 independent transformation
events were observed when ten tobacco leaves were bombarded with two different
chloroplast vectors, pLD-JW1 and pLD-JW2, suggesting that there was no inhibitory effect
of PA. Among clones tested, in both constructs, all were chloroplast transformants. No
spontaneous mutants or nuclear transformants were observed (see Fig. 1D). Because all
chloroplast transgenic lines were anticipated to contain similar levels of foreign gene
expression [7], only one or two independent lines were characterized further.
3.3. Chloroplast integration of transgenes and homoplasmy
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Southern blots were done to further verify that the trans-genes had been integrated into the
chloroplast genome and to determine homoplasmy (containing only transformed chloroplast
genomes) or heteroplasmy (containing both transformed and untransformed chloroplast
genomes). Total plant DNA was digested with the enzyme BglII which generated a 4.4 kb
fragment in wild type, 5.2 and 3 kb fragments in pLD-JW1 transgenic lines, and 6.8 and 3
kb fragments in pLD-JW2 transgenic lines when hybridized with a 0.81 kb probe made from
chloroplast flanking sequences (see Fig. 2A–D). The blots were also hybridized with a 0.52
kb probe made from the pag coding sequence (see Fig. 2E). All of the pLD-JW2 plants
appeared to be homoplasmic. In the pLD-JW1 plants, the transgenic line appeared to be
heteroplasmic, which is not uncommon to find in T0 plants. T0 refers to first generation
transgenic lines and T1 refers to second generation lines obtained by germination of seeds
from T0. However, germination of seeds from this T0 transgenic line on 500 μg/ml of
spectinomycin resulted in T1 plants that were homoplasmic (Fig. 2F).
3.4. PA expression in transgenic chloroplasts
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Western blots were performed on transgenic lines containing the two different constructs.
Full length 83 kDa polypeptide was detected on blots, confirming PA expression in
transgenic lines and absence of unique proteases that cleave PA in plant cells (see Fig. 3A–
C). Presence of active furin or trypsin-like proteases would have resulted in a 63 kDa protein
due to cleavage at the sequence RKKR (amino acids 164–167). The sequence FFD at
residues 312–314 is another site that is highly sensitive to chymotrypsin-like enzymes, and
cleavage would have resulted in 47 and 37 kDa fragments. No other cleaved PA products
were observed (see full length blots shown), demonstrating stability of chloroplast-derived
PA.
Additional Western blots were done comparing two different detergents in the extraction
buffers, CHAPS and SDS, and both were found to extract PA equally well (see Fig. 3C).
The supernatant and the homogenate were also found to be comparable in the pLD-JW2 line
suggesting that most of the PA is in the soluble fraction and that the chaperone did not fold
PA into cuboidal crystals. After storage for 2 days at 4 °C and −20 °C, the PA in plant crude
extracts is quite stable (see Fig. 3C). Powdered leaf was stored at −80 °C for several months
before performing Western blots or functional assays; this did not result in any noticeable
decrease in PA quantity or functionality. This should facilitate long term storage of
Vaccine. Author manuscript; available in PMC 2012 October 26.
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harvested leaves before extraction of PA for vaccine production. Native PA has been shown
to be highly unstable due to proteolysis-sensitive sites, which have been modified to confer
better stability [31].
3.5. Quantification of PA in transgenic chloroplasts
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Using ELISA, a standard curve was obtained with the purified PA, diluted to different
concentrations in coating buffer. To estimate the expression levels of recombinant PA
protein, the known concentrations of transgenic plant’s total soluble protein was compared
with that of the known concentrations of purified PA antibody complex (standard curve).
The PA protein levels of the pLD-JW1and pLD-JW2 homoplasmic transgenic lines of T1
generation under the normal illumination pattern (16 h light and 8 h dark) reached up to 2.7
and 1.7% of total soluble protein, in mature leaves, respectively. The psbA regulatory
sequences, including the promoters and UTRs, have been shown to enhance translation and
accumulation of foreign proteins under continuous light [12]. Therefore, pLD-JW1 T1
transgenic plants were placed under continuous light exposure (24 h light). Young, mature,
and old leaves were collected after 3 and 5 days of continuous illumination. The PA
expression patterns of JW1 in terms of percentage of total soluble protein were determined
for 3 and 5 days of continuous illumination. The percentage of PA in the total soluble
protein of JW1 plants reached a maximum of 18.1 and 13.4% in mature leaves of plants
exposed to continuous light for 5 and 3 days, respectively. The maximum PA expression
was observed in mature leaves compared to young and old leaves (Fig. 4). The decrease in
PA expression in old plants could be due to degradation of the proteins due to senescence.
The amount of PA present per plant and the relative yield from young, mature and old leaves
were estimated based on the different parameters of the biomass of transgenic plants (Table
1). Under the consistent environmental conditions provided in the plant growth chamber, a
total of 172 mg of PA could be obtained from each plant with a maximum of 92.7%
contribution from mature leaves, 4.8% from young leaves and 2.3% from old leaves. The
large contribution of PA from the mature leaves is due to the high number of chloroplasts in
mature leaves and the high copy number of chloroplast genomes (up to 10,000 copies per
cell) resulting in very high levels of PA expression in mature leaves (2.56 mg/g fresh
weight). The large size of mature leaves and the presence of more mature leaves per plant
also add to their contribution.
3.6. PA functionality determined by macrophage lysis

NIH-PA Author Manuscript

Supernatant and homogenate samples from both T0 constructs, pLD-JW1 and pLD-JW2,
were tested. Two different buffers were used to extract proteins—one contained CHAPS
detergent and one did not have any detergent. The functionality of the chloroplast-derived
PA was determined by its ability to internalize the lethal factor and cause lysis of cultured
mouse macrophages. The percentage macrophage viability was determined using the ability
of live but not dead cells to reduce a water-soluble yellow dye, MTT (3-[4,5dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) to an insoluble purple formazan
product. The transgenic plants were shown to produce fully functional PA (see Fig. 5A). A
comparative assay was done on the supernatant (containing the soluble fraction) and
homogenate parts (contains soluble and membrane fractions) of the T0 generation of pLDJW1, pLD-JW2 and wild type plants. Both the supernatant and homogenate fractions of
pLD-JW1 showed similar functional activity, suggesting that most of the PA is present in
the soluble fraction. In pLD-JW2, the supernatant showed higher functional activity than the
homogenate as evident by the activity at 100-fold greater dilution, where the percentage
viability of supernatant sample is much less than the homogenate sample. This could
possibly be due to interference of membranes in the lysis assays, which are removed by
centrifugation in the supernatant fractions. To check the possible interference of other
proteins in the crude plant extract or the components of the extraction buffer, the functional
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assays were carried out using the supernatant and homogenate of wild type untransformed
plants and the extraction buffer; none of these showed any detectable macrophage lysis
activity. This clearly shows that there is no toxicity to macrophage cells from the
components of plant extracts or the extraction buffer. The activity of purified PA (500 ng/
ml) was used as the standard to quantify unknown samples. Having determined that
supernatant fractions contain most of the PA, further analysis was done with supernatants on
next generation (T1) pLD-JW1 transgenic plants to determine the functionality of the PA in
the subsequent generations. To determine the stability of the PA during storage, functional
assays were done on the plant supernatant extracts stored at −20 °C for 2 and 7 days. The
PA stored for 2 and 7 days showed similar activity, which suggests that there is no
degradation of PA upon storage (see Fig. 5B), confirming that chloroplast-derived antigens
are quite stable during storage and transportation. The extracts of wild type plants and
transgenic plants had no macrophage lysis activity in the absence of LF. Crude plant extracts
contained up to 5 μg/ml functional PA, confirming expression of high levels of functional
PA in T0 plants (see Fig. 5A). Much higher macrophage lysis activity was observed in
supernatant samples from T1 pLD-JW1 transgenic lines, showing they contained
approximately 12–25 μg functional PA/ml (see Fig. 5B). The higher activity in T1 compared
T0 plants could be due to homoplasmy achieved in T1 generation but not in T0 plants (as
shown in Fig. 2F).
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3.7. Potential application of chloroplast-expressed PA
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The threat of biological warfare and terrorism is real. The most effective way to prevent or
deter use of anthrax as a weapon would be to produce an efficacious and inexpensive
vaccine. Plants are an economical and convenient way to produce recombinant proteins,
without human or animal pathogen contamination. In an area of one acre about 8000 tobacco
plants can be cultivated. At an average yield of 172 mg of PA per plant (Table 1), a total of
1.37 kg PA could be obtained per acre per single cutting of Petit Havana. A total of 4.12 kg
of PA could be expected from three cuttings each year. If we assume that there is 50% loss
of PA during purification from plant extracts (loss of foreign protein is generally between 30
and 90%), and at 5 μg PA per dose (current vaccine is in a range of 1.75–7 μg PA as per
[20]), one could produce about 400 million doses of vaccine per acre of tobacco. This
calculation assumes a low yield of tobacco from an experimental cultivar. However,
commercial cultivars yield up to 40 t of fresh leaves (40,000 kg in three cuttings as per [15])
as opposed to 2.2 t in Petit Havana; therefore, production could be up to 37.45 kg PA per
acre based on current expression levels and 50% loss during purification. An increase of
18.17-fold could be observed in a commercial cultivar compared to the experimental
cultivar. Thus a few acres of transgenic tobacco could meet the world’s need for anthrax
vaccine. Transgenic plants expressing human therapeutic proteins via the chloroplast
genome have been grown already in the field, after obtaining appropriate USDA permit by
Chlorogen Inc. Taken together, this study opens the door to large-scale production of an
improved vaccine.
In addition, this study should pave the way to develop edible anthrax vaccines to control
anthrax outbreaks among wildlife and domestic livestock. There have been recent anthrax
outbreaks in deer and livestock in September 2001 in Del Rio, TX, in cattle and horses in
Minnesota in June–July 2000, in cattle, horses, and bison in North Dakota in August 2000,
and in cattle in Nebraska in January 2001. Currently there is no vaccine considered suitable
for protecting wild-life (USDA, 2002, fact sheet).
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Fig. 1.
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Tobacco constructs and PCR confirmation of chloroplast transgene integration. (A) The
pLD-JW1 vector used for chloroplast transformation. The trnI and trnA genes were used as
flanking sequences for homologous recombination. The constitutive 16 s rRNA promoter
(“P”) was used to regulate transcription. The aadA gene conferring spectinomycin resistance
was used for selection of transgenic shoots. The pag gene coding for anthrax protective
antigen was regulated by the psbA promoter and 5′-UTR (5UTR) and 3′-UTR (T) elements.
(B) The pLD-JW2 construct was made by adding orf1, 2 from B. thuringiensis to the pLDJW1 vector. (C) Scheme showing PCR with the primers 3P and 3M to investigate
chloroplast transgene integration. The 3P primer anneals to the native chloroplast genome
and the 3M primer anneals to the aadA gene, generating a 1.65 kb PCR product in
chloroplast transgenic lines. (D) Analysis of randomly selected clones. Lane 1: 1 kb plus
DNA ladder; lane 2: negative control wild type tobacco plant DNA; lane 3: positive
transgenic plant DNA (pLD-5′-UTR/HIS/THR/IFNα2b); lane 4–8: five independent
transgenic lines tested.
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Fig. 2.
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Southern blots to investigate site of transgene integration and determine homoplasmy or
heteroplasmy in T0 and T1 generation. Schematic diagram of expected products from
digestion of wild type untransformed plant (A); plants transformed with pLD-JW1 (B); or
pLD-JW2 (C). (D) Flanking sequence probe showing heteroplasmy in pLD-JW1 line and
homoplasmy in pLD-JW2 lines. Lane 1: wild type; lane 2: pLD-JW1; lanes 3–5: pLD-JW2
transgenic lines of T0 generation. (E) pag sequence probe showing presence of pag in
transgenic lines of T0 generation. Lane 1: wild type; lane 2: pLD-JW1; lanes 3–5: pLD-JW2
transgenic lines. (F). Flanking sequence probe showing homoplasmy in pLD-JW1 line and
pLD-JW2 lines. Lane 1: wild type; lanes 2 and 3: pLD-JW1; lanes 4 and 5: pLD-JW2
transgenic lines of T1 generation.
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Fig. 3.
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Western blots demonstrating PA expression of transgenic lines containing the different
constructs. (A) Western blot of pLD-JW1 T1 transgenic line. Lane 1: wild type; lane 2:
precision plus protein standard; lane 3: 20 ng PA; lane 4: 10 ng PA; lane 5: 5 ng PA; lane 6:
1:10 dilution pLD-JW1 line; lane 7: 1:20 dilution pLD-JW1 line. (B) Western blot of pLDJW2 T1 transgenic line. Lane 1: wild type; lane 2: precision plus protein standard; lane 3: 20
ng PA; lane 4: 10 ng PA; lane 5: 5 ng PA; lane 6: blank; lane 7: 1:10 dilution pLD-JW2 line
1; lane 8: 1:20 dilution pLD-JW2 line 1; lane 9: 1:10 dilution pLD-JW2 line 2; lane 10: 1:20
dilution pLD-JW2 line 2. (C) Western blot comparing extraction buffers, containing CHAPS
and SDS, and both, and measuring stability of extracts at 4 and −20 °C: Sup: supernatant
fraction; Hom: homogenate (soluble and insoluble fractions); construct used: pLD-JW2.
Lane1: SDS, homogenate −20 °C; lane2: SDS, homogenate, 4 °C; lane3: SDS, supernatant,
−20 °C; lane4: SDS, supernatant, 4 °C; lane5: CHAPS, homogenate, −20 °C; lane6:
CHAPS, homogenate, 4 °C; lane7: CHAPS, supernatant, −20 °C; lane8: CHAPS,
supernatant, 4 °C.
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Fig. 4.
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Quantification of PA of JW1 plants of T1 generation using ELISA. Histogram of percentage
of PA in total soluble protein in fresh tissue of young, mature, old leaves of plant in 16 h
light and 8 h dark (day 0), 3 day continuous illumination and 5 day continuous illumination.
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Fig. 5.
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Macrophage cytotoxic assays for extracts from transgenic plants. (A) Supernatant and
homogenate samples from T0 pLD-JW1 tested (proteins extracted in buffer containing no
detergent and MTT added after 10 h): (▼) pLD-JW1 supernatant; (▽) pLD-JW1
homogenate; (■) pLD-JW2 supernatant; (□) pLD-JW2 homogenate; (×) PA 500 ng/ml; (⧗)
extraction buffer; (●) control wild type supernatant; (○) control wild type homogenate. (B)
Supernatant samples from T1 pLD-JW1 tested (proteins extracted in buffer containing no
detergent and MTT added after 5 h): (■) pLD-JW1 (extract stored 2 days); (□) pLD-JW1
(extract stored 7 days); (×) PA 5 μg/ml; (●) control wild type (extract stored 2 days); (○)
control wild type (extract stored 7 days); (▲) control wild type no LF (extract stored 2
days); (△) control wild type no LF (extract stored 7 days); (⧗) control pLD-JW1 no LF
(extract stored 2 days); (⧖) control pLD-JW1 no LF (extract stored 7 days).
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3.2

7.8

4.5

Young

Mature

Old

5

8

2.5

Average weight (g)/leaf

0.180

2.56

1.05

PA (mg/g) in fresh leaf

0.9

20.48

2.625

Amount of PA (mg) per leaf

Young: small, tender leaves from the top; mature: large, dark leaves from the middle; old: bleached leaves at the bottom.

Total amount of recombinant PA per plant

Leaves per plant

Leaf age

The yield of PA expressed in pLD-JW1 tobacco T1 transgenic line relative to its biomass

172.19

4.05

159.74

8.4

Amount of PA (mg) per age
group

100

2.35

92.76

4.80

Percentage of PA in relation to whole
plant
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